A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

Study Summary

The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).

Conditions

Hidradenitis Suppurativa (HS)

Interventions / Drugs

Povorcitinib

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment617 participants

Primary Completion—

Lead SponsorIncyte Corporation

Data Retrieved2026-04-11 02:55:29.647696+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.